Bristol Myers Squibb (BMY) ended the recent trading session at $56.29, demonstrating a -0.16% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain ...

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under ...

Welcome to “Sector Spotlight,” where The Fly looks at a new industry every week and highlights its happenings. Stay Ahead of the ...

Jefferies has recently raised Bristol-Myers Squibb Co (BMY) stock to Buy rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the ...

Of the more than 7.7 million people estimated to be living with sickle cell disease, more than 80% were in sub-Saharan Africa ...

Bristol Myers Squibb Co. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety coupled to a DNA-binding protein Ikaros (IKZF1 ...

The FDA has approved Cobenfy, a new drug to treat people with schizophrenia that comes with fewer side effects.

Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $55.74 which represents a slight increase of $0.38 or 0.69% from the prior close of $55.36. The stock opened at $55.5 and ...

Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer’s-related psychosis during the ...

Bristol Myers (BMY) new psychiatric drug Cobenfy is effective in treating schizophrenia without “the serious side effects’ of other older ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Bristol Myers Squibb Co. said its new schizophrenia drug is off to a better start than similar recently launched treatments, ...